Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.50 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15846816 | 0.78 | LMNA (0.52) | NPC1RAB9ATSHRALDH1A1GAA | |
| SCHEMBL9364280 | 0.78 | CES2 (0.50) | CES2CES1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL28541908 | 0.78 | CYP2C9 (0.46) | L3MBTL1SMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL229639 | 0.77 | LMNA (0.58) | CES2CES1SMN1; SMN2TSHRALDH1A1 | |
| SCHEMBL28775846 | 0.77 | CES2 (0.59) | CES2CES1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL247590 | 0.77 | CES2 (0.59) | CES2CES1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL22619 | 0.77 | CES2 (0.59) | CES2CES1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL22115811 | 0.77 | CES2 (0.59) | CES2CES1L3MBTL1SMN1; SMN2NPC1 | |
| SCHEMBL28551022 | 0.76 | PARP1 (0.53) | L3MBTL1SMN1; SMN2NPC1RAB9AALOX15 | |
| SCHEMBL4625785 | 0.75 | CA1 (0.64) | CES2CES1SMN1; SMN2RAB9ACA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | claimed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | claimed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3071588-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015077292-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | SOMALOGIC, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| JP-4623828-B2 | — | — | 2011-02-02 | — | — | JP | claimed |
| EP-1102782-B1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1102782-A4 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2002-01-30 | — | — | EP | claimed |
| US-6335432-B1 | FOR FLUORESCENT HYBRIDIZATION PROBES FOR USE IN DIAGNOSIS, RESEARCH, AND THERAPY | BIO-RED LABORATORIES, INC. | 2002-01-01 | — | — | US | claimed |
| EP-1102782-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | Bio-Rad Laboratories (US) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008041-A9 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2000008041-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO-RAD LABORATORIES (US) | 2000-02-17 | — | — | WO | claimed |
| CN-109553703-B | Catalyst component for olefin polymerization and preparation method thereof | 中国石油化工股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-109553711-B | Catalyst component for olefin polymerization and catalyst thereof | 中国石油化工股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-109553706-B | Catalyst component for olefin polymerization, catalyst and application | 中国石油化工股份有限公司 | 2021-04-13 | — | — | CN | disclosed |
| US-6335432-B1 | FOR FLUORESCENT HYBRIDIZATION PROBES FOR USE IN DIAGNOSIS, RESEARCH, AND THERAPY | BIO-RED LABORATORIES, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1102782-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | Bio-Rad Laboratories (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008041-A9 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000008041-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO-RAD LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | CES2 770/4885CES1 842/4885L3MBTL1 2132/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | CES2 770/4885CES1 842/4885L3MBTL1 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.